Ciprofloxacin

Ciprofloxacin Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 185 adverse event reports referencing Ciprofloxacin, including 20 reports in which the animal died — a 1080.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Ciprofloxacin. Reported administration routes include Oral, Unknown, Ophthalmic, Intraocular. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Ciprofloxacin reports are Dog (167 reports), Cat (13 reports), Human (2 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (23), Shepherd Dog - German (10), Dog (unknown) (7) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Ciprofloxacin are Lethargy (see also Central nervous system depression in 'Neurological') (32), Vomiting (31), Emesis (30), Other abnormal test result NOS (23). Of the 183 reports with a coded outcome, Recovered/Normal is the leading category at 36.6%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Ciprofloxacin.